Today, @TheraPsil alongside @SabiMind and @FilamentHealth launched the first wellness-focused & stakeholder-funded psilocybin clinical trial.
Psychedelic research is about to change.
See full release here: https://t.co/TjytpuMEe3
Today we announced positive data from a phase 2 study of PEX010 in patients with alcohol use disorder. The study found that after 1 dose of #psilocybin, the mean % of heavy drinking days was reduced by more than 50% over the 12-week observation period.
https://t.co/AtolciQ98u
.@benlightburn@FilamentHealth discusses the company’s approach to psychedelic medicine, the case for natural botanical extracts rather than synthetic compounds, and its lead experimental therapy that targets methamphetamine use disorder.
https://t.co/SVSAkmmoM2
Today we announced the import of Peruvian coca leaf to our Vancouver R&D facility for the development of a botanical drug candidate to treat ADHD.
https://t.co/AHE8nHaIOw
A groundbreaking clinical trial will explore the use of psilocybin, the active compound in magic mushrooms, to combat opioid addiction. 🍄
This ‘first in the UK’ study aims to help prevent relapse with the power of psychedelics and psychological support.
https://t.co/F7vMXxmNcq
Today we announced a major expansion of our IP portfolio, with 12 new patents accepted in Australia, 5 in Canada, & 3 in the US. Filament holds a total of 46 allowed patents relating to the development & delivery of naturally-derived psychedelic APIs.
https://t.co/0SRNI414sn
Today we announced authorization by both @US_FDA & @GovCanHealth of a Phase 2 clinical trial studying PEX010 for methamphetamine use disorder. This is the first ever clinical trial to study the safety & efficacy of botanical #psilocybin for MAUD.
https://t.co/YMZFyVYmgS
We're pleased to report our Q1 2024 results, including important advancement of our drug development efforts in substance use disorders.
https://t.co/yVSoY5QhS2
Our CEO @benlightburn will be hosting an #AMA with @ceodotca at 12PM ET tomorrow to discuss our latest news and developments. Submit questions for Ben via: https://t.co/6s2BwB1nLm
We're pleased to report our 2023 year-end results including $2.1 million in revenue + @GovCanHealth approval of a Filament-sponsored Phase 2 clinical trial studying our botanical psilocybin for opioid use disorder at @UBC.
https://t.co/k7cM8mHHyZ
We're pleased to announce that Michael Messinger has been appointed to our Board of Directors, bringing over 20 years' experience in biotech finance roles.
https://t.co/NcL1bDmCIG
Can the power of magic mushrooms overcome the pull of alcohol use disorder? 🍄🍻
An upcoming study based in Canada aims to shed light on the potential for psilocybin’s role in battling the beast that is alcohol addiction. https://t.co/sZStp3CnJx
The @UCalgary is about to start a major study on psilocybin-assisted therapy for the treatment of alcoholism.
British Columbia’s @FilamentHealth will provide magic mushroom extract needed for the research.
$FLHLF #psychedelics#psilocybin
https://t.co/k5b35IpIxS
Today we announced that we have shipped our botanical psilocybin drug candidate, PEX010, to 4 countries for clinical trials at leading research institutions including @JohnsHopkins.
https://t.co/AhuauZWQFt
2024 is set to be a watershed year for #Psychedelics.
Alongside an influx of biotech investment in the UK, the industry has seen significant milestones set to accelerate the sector, return confidence & advance #MentalHealth innovations.
Find out more. 👇
https://t.co/Zq1c2V8IIp
"We developed specific technology that has allowed us to create the first & only pharmaceutical grade natural psychedelic drug candidates." - CEO @benlightburn spoke to @PharmExec Magazine about our novel approach to psychedelic drug development.
https://t.co/ZGWZsajkic